Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company's most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson's disease. Yumanity's drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity's pipeline consists of additional programs focused on Lewy body dementia, multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease. Show more
Location: 80 Guest St Fl 5, Massachusetts, 02135-2071, US | Website: www.proteostasis.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
1.018B
52 Wk Range
$N/A - $N/A
Previous Close
$N/A
Open
$N/A
Volume
N/A
Day Range
$N/A - $N/A
Enterprise Value
0.00
Cash
159.3M
Avg Qtr Burn
N/A
Insider Ownership
19.62%
Institutional Own.
22.57%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|